Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,074 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $29.11, for a total value of $264,144.14. Following the transaction, the insider now directly owns 95,648 shares of the company’s stock, valued at approximately $2,784,313.28. The trade was a 8.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Friday, November 15th, Catriona Yale sold 9,061 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.73, for a total value of $251,261.53.
• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.62, for a total value of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.53, for a total transaction of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.03, for a total value of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total transaction of $152,075.00.

Akero Therapeutics Stock Down 1.1 %

AKRO opened at $28.40 on Friday. The company has a market capitalization of $1.98 billion, a PE ratio of -7.57 and a beta of -0.23. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a fifty-two week low of $15.32 and a fifty-two week high of $37.00. The business has a 50-day moving average of $30.90 and a 200-day moving average of $27.37.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Equities research analysts forecast that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares during the last quarter. Eastern Bank acquired a new stake in Akero Therapeutics in the 3rd quarter worth approximately $100,000. Summit Financial Wealth Advisors LLC bought a new stake in Akero Therapeutics during the third quarter worth approximately $205,000. Victory Capital Management Inc. acquired a new position in Akero Therapeutics during the third quarter valued at approximately $211,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Akero Therapeutics during the third quarter valued at approximately $265,000.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup began coverage on Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Akero Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $46.83.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.